mitoxantrone has been researched along with Allergic Encephalomyelitis in 18 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mitoxantrone is a synthetic anthracenedione recently approved by the FDA for the treatment of worsening relapsing-remitting (RR), secondary progressive (SP), and progressive relapsing (PR) multiple sclerosis (MS)." | 8.82 | Review of mitoxantrone in the treatment of multiple sclerosis. ( Herndon, R; Jeffery, DR, 2004) |
| "Mitoxantrone has proved efficacy in treatment of multiple sclerosis (MS)." | 8.12 | Does physical exercise improve or deteriorate treatment of multiple sclerosis with mitoxantrone? Experimental autoimmune encephalomyelitis study in rats. ( Abdallah, DM; El Achy, S; El-Abhar, HS; El-Emam, MA; Gowayed, MA, 2022) |
| "Escalation therapy with mitoxantrone (MX) in highly active multiple sclerosis is limited by partially dose-dependent side-effects." | 7.75 | ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis. ( Chan, A; Cotte, S; Dörr, J; Gold, R; Huber, B; Koepsell, H; König, N; Kruse, N; Lühder, F; Montalban, X; Pannek, H; Paul, F; Starck, M; Tellez, N; von Ahsen, N; Winkelmann, A; Zettl, UK; Zipp, F, 2009) |
| "The side effects of cancer chemotherapeutic agents such as mitoxantrone (MIT) in multiple sclerosis (MS) patients justify the search for less toxic drugs." | 7.74 | Therapeutic effect of anthracene-based anticancer agent ethonafide in an animal model of multiple sclerosis. ( Bai, XF; Campagnolo, DI; Dorr, RT; Huang, J; Piao, WH; Shi, FD; Vollmer, TL; Wong, R, 2007) |
| "Mitoxantrone, a new antineoplastic anthracenedione drug, suppressed the development of experimental allergic encephalomyelitis (EAE) in rats when administered during the incubation period." | 7.67 | Regional suppression, therapy after onset and prevention of relapses in experimental allergic encephalomyelitis by mitoxantrone. ( Levine, S; Saltzman, A, 1986) |
| "The effect of treatment with the antineoplastic, immunomodulatory agent mitoxantrone on the course of acute and relapsing experimental allergic encephalomyelitis (EAE) in the mouse has been studied." | 7.67 | Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone. ( Knobler, RL; Lavasa, M; Lublin, FD; Viti, C, 1987) |
| "Treatment of rats with a developing or an established lesion of experimental allergic encephalomyelitis (EAE) with mitoxantrone (Novantrone) suppressed the hind limb paralysis associated with the disease." | 7.67 | Suppression of experimental allergic encephalomyelitis by mitoxantrone. ( Kerwar, SS; Levine, S; McReynolds, RA; Oronsky, AL; Ridge, SC; Sloboda, AE, 1985) |
| "Mitoxantrone is a synthetic anthracenedione recently approved by the FDA for the treatment of worsening relapsing-remitting (RR), secondary progressive (SP), and progressive relapsing (PR) multiple sclerosis (MS)." | 4.82 | Review of mitoxantrone in the treatment of multiple sclerosis. ( Herndon, R; Jeffery, DR, 2004) |
| "Mitoxantrone has proved efficacy in treatment of multiple sclerosis (MS)." | 4.12 | Does physical exercise improve or deteriorate treatment of multiple sclerosis with mitoxantrone? Experimental autoimmune encephalomyelitis study in rats. ( Abdallah, DM; El Achy, S; El-Abhar, HS; El-Emam, MA; Gowayed, MA, 2022) |
| "Previously we showed that BBR3378, a novel analog of the anticancer drug mitoxantrone, had the ability to ameliorate ascending paralysis in MOG35-55-induced experimental autoimmune encephalomyelitis (EAE), a murine model of human multiple sclerosis, without the drug-induced cardiotoxicity or lymphopenia associated with mitoxantrone therapy." | 3.83 | An aza-anthrapyrazole negatively regulates Th1 activity and suppresses experimental autoimmune encephalomyelitis. ( Clark, MP; Hazelhurst, LA; Hwang, ES; Leaman, DW; Quinn, A, 2016) |
| "Mitoxantrone is one of the few FDA-approved drugs available to treat rapidly progressing forms of multiple sclerosis; however, its utilization is compromised by a cardiotoxic potential and the risk of mitoxantrone-induced leukemia." | 3.77 | A novel aza-anthrapyrazole blocks the progression of experimental autoimmune encephalomyelitis after the priming of autoimmunity. ( Gunning, W; Hacker, M; Kiraly, A; Koffman, B; Quinn, A; Rasche, S, 2011) |
| "Escalation therapy with mitoxantrone (MX) in highly active multiple sclerosis is limited by partially dose-dependent side-effects." | 3.75 | ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis. ( Chan, A; Cotte, S; Dörr, J; Gold, R; Huber, B; Koepsell, H; König, N; Kruse, N; Lühder, F; Montalban, X; Pannek, H; Paul, F; Starck, M; Tellez, N; von Ahsen, N; Winkelmann, A; Zettl, UK; Zipp, F, 2009) |
| "The side effects of cancer chemotherapeutic agents such as mitoxantrone (MIT) in multiple sclerosis (MS) patients justify the search for less toxic drugs." | 3.74 | Therapeutic effect of anthracene-based anticancer agent ethonafide in an animal model of multiple sclerosis. ( Bai, XF; Campagnolo, DI; Dorr, RT; Huang, J; Piao, WH; Shi, FD; Vollmer, TL; Wong, R, 2007) |
| " To elucidate possible mechanisms behind such phenomena the effects were studied of mitoxantrone (Mx) and cyclosporin A (CsA) given at high and low doses on clinical course, and on autoreactive T- and B-cell responses in actively induced experimental allergic encephalomyelitis (EAE) in Lewis rats." | 3.68 | Immunopharmacologic modulation of experimental allergic encephalomyelitis: low-dose cyclosporin-A treatment causes disease relapse and increased systemic T and B cell-mediated myelin-directed autoimmunity. ( Diener, P; Link, H; Mustafa, M; Olsson, T; Sun, JB, 1993) |
| "Mitoxantrone was used as an immunosuppressive probe to elucidate a means for the control of experimental allergic encephalomyelitis (EAE) induced in Biozzi AB/H mice following injection of spinal cord homogenate emulsified in Freund's adjuvant." | 3.68 | Control of immune-mediated disease of the central nervous system requires the use of a neuroactive agent: elucidation by the action of mitoxantrone. ( Baker, D; Davison, AN; O'Neill, JK; Turk, JL, 1992) |
| "Mitoxantrone, a new antineoplastic anthracenedione drug, suppressed the development of experimental allergic encephalomyelitis (EAE) in rats when administered during the incubation period." | 3.67 | Regional suppression, therapy after onset and prevention of relapses in experimental allergic encephalomyelitis by mitoxantrone. ( Levine, S; Saltzman, A, 1986) |
| "The effect of treatment with the antineoplastic, immunomodulatory agent mitoxantrone on the course of acute and relapsing experimental allergic encephalomyelitis (EAE) in the mouse has been studied." | 3.67 | Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone. ( Knobler, RL; Lavasa, M; Lublin, FD; Viti, C, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (16.67) | 18.7374 |
| 1990's | 4 (22.22) | 18.2507 |
| 2000's | 7 (38.89) | 29.6817 |
| 2010's | 3 (16.67) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| El-Emam, MA | 1 |
| El Achy, S | 1 |
| Abdallah, DM | 1 |
| El-Abhar, HS | 1 |
| Gowayed, MA | 1 |
| Clark, MP | 1 |
| Leaman, DW | 1 |
| Hazelhurst, LA | 1 |
| Hwang, ES | 1 |
| Quinn, A | 2 |
| Cotte, S | 1 |
| von Ahsen, N | 1 |
| Kruse, N | 1 |
| Huber, B | 1 |
| Winkelmann, A | 1 |
| Zettl, UK | 1 |
| Starck, M | 1 |
| König, N | 1 |
| Tellez, N | 1 |
| Dörr, J | 1 |
| Paul, F | 1 |
| Zipp, F | 1 |
| Lühder, F | 1 |
| Koepsell, H | 1 |
| Pannek, H | 1 |
| Montalban, X | 1 |
| Gold, R | 2 |
| Chan, A | 2 |
| Kiraly, A | 1 |
| Koffman, B | 1 |
| Hacker, M | 1 |
| Gunning, W | 1 |
| Rasche, S | 1 |
| Alves, CC | 1 |
| Castro, SB | 1 |
| Costa, CF | 1 |
| Dias, AT | 1 |
| Alves, CJ | 1 |
| Rodrigues, MF | 1 |
| Teixeira, HC | 1 |
| Almeida, MV | 1 |
| Ferreira, AP | 1 |
| Weilbach, FX | 1 |
| Toyka, KV | 1 |
| Cavaletti, G | 1 |
| Cavalletti, E | 1 |
| Crippa, L | 1 |
| Di Luccio, E | 1 |
| Oggioni, N | 1 |
| Mazzanti, B | 1 |
| Biagioli, T | 1 |
| Sala, F | 1 |
| Sala, V | 1 |
| Frigo, M | 1 |
| Rota, S | 1 |
| Tagliabue, E | 1 |
| Stanzani, L | 1 |
| Galbiati, S | 1 |
| Rigolio, R | 1 |
| Zoia, C | 1 |
| Tredici, G | 1 |
| Perseghin, P | 1 |
| Dassi, M | 1 |
| Riccio, P | 1 |
| Lolli, F | 1 |
| Webb, M | 1 |
| Tham, CS | 1 |
| Lin, FF | 1 |
| Lariosa-Willingham, K | 1 |
| Yu, N | 1 |
| Hale, J | 1 |
| Mandala, S | 1 |
| Chun, J | 1 |
| Rao, TS | 1 |
| Jeffery, DR | 1 |
| Herndon, R | 1 |
| Neuhaus, O | 1 |
| Kieseier, BC | 1 |
| Hartung, HP | 1 |
| Piao, WH | 1 |
| Wong, R | 1 |
| Bai, XF | 1 |
| Huang, J | 1 |
| Campagnolo, DI | 1 |
| Dorr, RT | 1 |
| Vollmer, TL | 1 |
| Shi, FD | 1 |
| Mustafa, M | 1 |
| Diener, P | 1 |
| Sun, JB | 1 |
| Link, H | 1 |
| Olsson, T | 1 |
| Gonsette, RE | 1 |
| Baker, D | 2 |
| O'Neill, JK | 2 |
| Davison, AN | 2 |
| Turk, JL | 2 |
| Watson, CM | 1 |
| Levine, S | 2 |
| Saltzman, A | 1 |
| Lublin, FD | 1 |
| Lavasa, M | 1 |
| Viti, C | 1 |
| Knobler, RL | 1 |
| Ridge, SC | 1 |
| Sloboda, AE | 1 |
| McReynolds, RA | 1 |
| Oronsky, AL | 1 |
| Kerwar, SS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Proof of Concept Study Evaluating the Reduction of Mitoxantrone-induced Cardiotoxicity and Neurological Outcome in the Combined Use of Mitoxantrone and Dexrazoxane (Cardioxane®) in Multiple Sclerosis (MSCardioPro)[NCT01627938] | Phase 2 | 50 participants (Anticipated) | Interventional | 2012-04-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for mitoxantrone and Allergic Encephalomyelitis
| Article | Year |
|---|---|
Review of mitoxantrone in the treatment of multiple sclerosis.
Topics: Animals; Clinical Trials as Topic; Encephalomyelitis, Autoimmune, Experimental; Humans; Immunosuppre | 2004 |
Mitoxantrone in multiple sclerosis.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Encephalomyelitis, Autoimmune, Experimenta | 2006 |
Mitoxantrone immunotherapy in multiple sclerosis.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Encephalomyelitis, Autoimmune, Experimental; Humans | 1996 |
15 other studies available for mitoxantrone and Allergic Encephalomyelitis
| Article | Year |
|---|---|
Does physical exercise improve or deteriorate treatment of multiple sclerosis with mitoxantrone? Experimental autoimmune encephalomyelitis study in rats.
Topics: Animals; bcl-2-Associated X Protein; Encephalomyelitis, Autoimmune, Experimental; Forkhead Transcrip | 2022 |
An aza-anthrapyrazole negatively regulates Th1 activity and suppresses experimental autoimmune encephalomyelitis.
Topics: Animals; Anthracyclines; Apoptosis; Autoimmunity; Cell Proliferation; Cytokines; Encephalomyelitis, | 2016 |
ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.
Topics: Adult; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Sub | 2009 |
A novel aza-anthrapyrazole blocks the progression of experimental autoimmune encephalomyelitis after the priming of autoimmunity.
Topics: Animals; Autoimmunity; Cytokines; Disease Models, Animal; Disease Progression; Encephalomyelitis, Au | 2011 |
Anthraquinone derivative O,O'-bis-(3'-iodopropyl)-1,4-dihydroxyanthraquinone modulates immune response and improves experimental autoimmune encephalomyelitis.
Topics: Animals; Cell Line; Cell Movement; Cell Survival; Cytokines; Encephalomyelitis, Autoimmune, Experime | 2012 |
The cardioprotector dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis.
Topics: Animals; Apoptosis; Cardiotonic Agents; Chelating Agents; Dose-Response Relationship, Drug; Drug The | 2004 |
Pixantrone (BBR2778) reduces the severity of experimental allergic encephalomyelitis.
Topics: Acute Disease; Animals; Cell Division; Cells, Cultured; Chronic Disease; Encephalomyelitis, Autoimmu | 2004 |
Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Inter | 2004 |
Therapeutic effect of anthracene-based anticancer agent ethonafide in an animal model of multiple sclerosis.
Topics: Acute Disease; Animals; Anthracenes; Antineoplastic Agents; Disease Models, Animal; Dose-Response Re | 2007 |
Immunopharmacologic modulation of experimental allergic encephalomyelitis: low-dose cyclosporin-A treatment causes disease relapse and increased systemic T and B cell-mediated myelin-directed autoimmunity.
Topics: Animals; Antibody-Producing Cells; Autoimmunity; B-Lymphocytes; Brain; Cyclosporine; Down-Regulation | 1993 |
Control of immune-mediated disease of the central nervous system requires the use of a neuroactive agent: elucidation by the action of mitoxantrone.
Topics: Animals; Blood-Brain Barrier; Encephalomyelitis, Autoimmune, Experimental; Immunosuppressive Agents; | 1992 |
Suppression of demyelination by mitoxantrone.
Topics: Animals; Encephalomyelitis, Autoimmune, Experimental; Female; Immunosuppressive Agents; Leukocytes; | 1991 |
Regional suppression, therapy after onset and prevention of relapses in experimental allergic encephalomyelitis by mitoxantrone.
Topics: Animals; Encephalomyelitis, Autoimmune, Experimental; Female; Injections, Intraperitoneal; Injection | 1986 |
Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone.
Topics: Acute Disease; Animals; Encephalomyelitis, Autoimmune, Experimental; Immunization; Mice; Mice, Inbre | 1987 |
Suppression of experimental allergic encephalomyelitis by mitoxantrone.
Topics: Animals; Anthraquinones; Cyclophosphamide; Drug Administration Schedule; Encephalomyelitis, Autoimmu | 1985 |